- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
December 2, 2024Robins Kaplan LLP Announces 2025 Partners
-
November 20, 2024Eighth Circuit Affirms U.S. Merchants Victory in Trade Dress Infringement Case
-
November 15, 2024Lauren Coppola Named an Emerging Leader by Profiles in Diversity Journal
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
December 2024A Landmark Victory for Disabled Homeless Veterans: Q&A with the Trial Team
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Novartis Pharms. Corp. v. Alembic Pharms. Ltd.
Entresto® (sacubitril/valsartan)
September 29, 2023
Case Name: Novartis Pharms. Corp. v. Alembic Pharms. Ltd., Civ. No. 22-1395-RGA, 2023 WL 6387975 (D. Del. Sept. 29, 2023) (Andrews, J.)
Drug Product and Patent(s)-in-Suit: Entresto® (sacubitril/valsartan); U.S. Patent No. 11,096,918 (“the ’918 patent”)
Nature of the Case and Issue(s) Presented: Previously, Novartis sued Noratech, MSN, and other defendants, alleging that each defendant’s ANDA products infringed various patents. As part of that previous litigation, Noratech and MSN provided to Novartis their ANDAs, product samples, and other confidential information subject to the protective order entered in that case. Novartis ultimately dismissed its infringement claims.
Novartis then filed this case asserting, “on information and belief,” that Noratech’s and MSN’s ANDA products (the same ANDA products accused in the previous case) infringe the ’918 patent. Noratech filed a motion to dismiss for failure to state a claim, and the MSN defendants filed a motion for judgment on the pleadings. Defendants argued that Novartis’s “on information and belief” allegations were insufficient, and that Novartis should have to plead infringement with greater specificity based on ANDAs, testing data, and other documents it obtained during the previous litigation. The court denied both motions.
Why Novartis Prevailed: The court had previously interpreted the protective order governing Defendants’ disclosures in the previous litigation as preventing use of that information to initiate other litigation. Thus, Novartis could not plead infringement with the additional detail that Defendants demanded. Moreover, the court reaffirmed application of the more “relaxed” Belcher pleading standard in ANDA infringement cases, including those asserting only non-OB-listed patents, like this one—ANDA infringement plaintiffs are held to a lower level of specificity than plaintiffs in other patent infringement cases.
MSN also moved for judgment of non-infringement, arguing that the ’918 patent claims an amorphous form of the claimed compound and its ANDA product requires a crystalline form. Consistent with recent trends, the court determined that it could not adjudicate infringement at this early stage—in particular, without expert testimony—and pleading that the ANDA product infringes was sufficient. The court went so far as to state that “an ANDA does not provide a complete answer to infringement.”
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.